FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200439401> ?p ?o ?g. }

• W4200439401 endingPage "1596" @default.
• W4200439401 startingPage "1596" @default.
• W4200439401 abstract "Abstract INTRODUCTION: There is expectation of using biomarkers to personalize treatment in MM. Yet, a successful treatment selection cannot be confirmed before 5 or 10 years of progression-free survival (PFS). Treatment individualization based on the probability of an individual patient to achieve undetectable MRD with a singular regimen, could represent a new model towards personalized treatment with fast assessment of its success. This idea has not been investigated previously. AIM: Develop a machine learning model to predict undetectable MRD in newly-diagnosed transplant-eligible MM patients, treated with a standard of care. METHODS: This study included a total of 278 newly-diagnosed and transplant-eligible MM patients treated with proteasome inhibitors, immunomodulatory drugs and corticosteroids. The training (n=152) and internal validation cohort (n=60) consisted of 212 active MM patients enrolled in the GEM2012MENOS65 trial. The external validation cohort was defined by 66 high-risk smoldering MM patients enrolled in the GEM-CESAR trial, which treatment differed only by the substitution of bortezomib by carfilzomib during induction and consolidation. RESULTS: We started by investigating patients' MRD status after VRD induction, HDT/ASCT and VRD consolidation according to their ISS and R-ISS, LDH levels, and cytogenetic alterations. Surprisingly, neither the ISS nor the R-ISS predicted significantly different MRD outcomes. Indeed, high LDH levels and del(17p13) were the only parameters associated with lower rates of undetectable MRD. Because these two features are relatively infrequent at diagnosis, we next aimed to evaluate other disease features and develop integrative, weighted and more effective models based on machine learning algorithms. Of 37 clinical and biological parameters evaluated, 17 were associated with MRD outcomes. These were subsequently modeled using logistic regression for machine learning classification, where the sum of the weighted coefficients multiplied by its input variable, is transformed into a probability outcome that ranges from 0 to 1 using a logit sigmoid function. The most effective model resulted from integrating cytogenetic [t(4;14) and/or del(17p13)], tumor burden (plasma cell [PC] clonality in bone marrow and CTCs in blood) and immune related (myeloid precursors, mature B cells, intermediate neutrophils, eosinophils, CD27 negCD38 pos T cells and CD56 brightCD27 neg NK cells) biomarkers. Of note, immune biomarkers displayed the highest coefficient weights and were determinant to predict patients' MRD status in this model. Data obtained for an individual patient can be substituted into our formula, which results in a numerical probability of achieving undetectable (&gt;0.5) vs persistent (&lt;0.5) MRD after treatment. If probability outcomes are &gt;0.685 or &lt;0.365 (observed in 102/212 patients), MRD outcomes are respectively predicted with higher confidence. Standard-confidence, high-confidence, and external validation predictions were accurate in 152/212 (71.7%), 85/102 (83.3%), and 48/66 (72.7%) patients respectively. Similarly, the external validation set exhibited a similar receiver operating characteristic (ROC) curve as the internal test set (AUC of 0.73 and 0.77 respectively). Patients predicted to achieve undetectable MRD using standard and high-confidence values showed longer PFS and overall survival (OS) than those with probability of persistent MRD. In fact, patients with &gt;0.687 probability of achieving undetectable MRD showed 86% PFS and 94% OS at five years, whereas those in whom persistent MRD was predicted (&lt;0.365), median PFS was 44 months, and 69% OS was observed at five years. These data indicate that the combination of cytogenetics, tumor burden in bone marrow plus peripheral blood, and immune profiling, may also be explored to identify a subset of patients that have a singular disease biology and long-term survival. CONCLUSION: We demonstrated that it is possible to predict patients' MRD status with significant accuracy, using an integrative, weighted model based on machine learning algorithms. Although immune biomarkers are not commonly used, the raw data from which these can be developed is generally obtained in diagnostic laboratories using flow cytometry to screen for PC clonality. Furthermore, we made the model available to facilitate its use in clinical practice at www.MRDpredictor.com. Disclosures Puig: Celgene, Janssen, Amgen, Takeda: Research Funding; Celgene: Speakers Bureau; Amgen, Celgene, Janssen, Takeda: Consultancy; Amgen, Celgene, Janssen, Takeda and The Binding Site: Honoraria. Cedena: Janssen, Celgene and Abbvie: Honoraria. Oriol: Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. De Arriba: Amgen: Consultancy, Honoraria; Glaxo Smith Kline: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Speakers Bureau; BMS-Celgene: Consultancy, Honoraria, Speakers Bureau. Martínez-López: Janssen, BMS, Novartis, Incyte, Roche, GSK, Pfizer: Consultancy; Roche, Novartis, Incyte, Astellas, BMS: Research Funding. Lahuerta: Celgene: Other: Travel accomodations and expenses; Celgene, Takeda, Amgen, Janssen and Sanofi: Consultancy. Rosinol: Janssen, Celgene, Amgen and Takeda: Honoraria. Bladé Creixenti: Janssen, Celgene, Takeda, Amgen and Oncopeptides: Honoraria. Mateos: Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria; Bluebird bio: Honoraria; GSK: Honoraria; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sea-Gen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene - Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron: Honoraria, Membership on an entity's Board of Directors or advisory committees. San-Miguel: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, SecuraBio, and Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees. Paiva: Bristol-Myers Squibb-Celgene, Janssen, and Sanofi: Consultancy; Adaptive, Amgen, Bristol-Myers Squibb-Celgene, Janssen, Kite Pharma, Sanofi and Takeda: Honoraria; Celgene, EngMab, Roche, Sanofi, Takeda: Research Funding." @default.
• W4200439401 created "2021-12-31" @default.
• W4200439401 creator A5015898454 @default.
• W4200439401 creator A5016479494 @default.
• W4200439401 creator A5018043620 @default.
• W4200439401 creator A5020420490 @default.
• W4200439401 creator A5028963447 @default.
• W4200439401 creator A5029159537 @default.
• W4200439401 creator A5032982185 @default.
• W4200439401 creator A5034182883 @default.
• W4200439401 creator A5034846592 @default.
• W4200439401 creator A5035866456 @default.
• W4200439401 creator A5047672322 @default.
• W4200439401 creator A5047866471 @default.
• W4200439401 creator A5050473364 @default.
• W4200439401 creator A5051606383 @default.
• W4200439401 creator A5053570733 @default.
• W4200439401 creator A5054952877 @default.
• W4200439401 creator A5055467929 @default.
• W4200439401 creator A5056460838 @default.
• W4200439401 creator A5056987348 @default.
• W4200439401 creator A5057189669 @default.
• W4200439401 creator A5059800672 @default.
• W4200439401 creator A5060669113 @default.
• W4200439401 creator A5064147442 @default.
• W4200439401 creator A5080697191 @default.
• W4200439401 creator A5083592777 @default.
• W4200439401 creator A5089163384 @default.
• W4200439401 creator A5089770876 @default.
• W4200439401 date "2021-11-05" @default.
• W4200439401 modified "2023-10-18" @default.
• W4200439401 title "A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable Measurable Residual Disease (MRD) in Transplant-Eligible Multiple Myeloma (MM)" @default.
• W4200439401 doi "https://doi.org/10.1182/blood-2021-145968" @default.
• W4200439401 hasPublicationYear "2021" @default.
• W4200439401 type Work @default.
• W4200439401 citedByCount "0" @default.
• W4200439401 crossrefType "journal-article" @default.
• W4200439401 hasAuthorship W4200439401A5015898454 @default.
• W4200439401 hasAuthorship W4200439401A5016479494 @default.
• W4200439401 hasAuthorship W4200439401A5018043620 @default.
• W4200439401 hasAuthorship W4200439401A5020420490 @default.
• W4200439401 hasAuthorship W4200439401A5028963447 @default.
• W4200439401 hasAuthorship W4200439401A5029159537 @default.
• W4200439401 hasAuthorship W4200439401A5032982185 @default.
• W4200439401 hasAuthorship W4200439401A5034182883 @default.
• W4200439401 hasAuthorship W4200439401A5034846592 @default.
• W4200439401 hasAuthorship W4200439401A5035866456 @default.
• W4200439401 hasAuthorship W4200439401A5047672322 @default.
• W4200439401 hasAuthorship W4200439401A5047866471 @default.
• W4200439401 hasAuthorship W4200439401A5050473364 @default.
• W4200439401 hasAuthorship W4200439401A5051606383 @default.
• W4200439401 hasAuthorship W4200439401A5053570733 @default.
• W4200439401 hasAuthorship W4200439401A5054952877 @default.
• W4200439401 hasAuthorship W4200439401A5055467929 @default.
• W4200439401 hasAuthorship W4200439401A5056460838 @default.
• W4200439401 hasAuthorship W4200439401A5056987348 @default.
• W4200439401 hasAuthorship W4200439401A5057189669 @default.
• W4200439401 hasAuthorship W4200439401A5059800672 @default.
• W4200439401 hasAuthorship W4200439401A5060669113 @default.
• W4200439401 hasAuthorship W4200439401A5064147442 @default.
• W4200439401 hasAuthorship W4200439401A5080697191 @default.
• W4200439401 hasAuthorship W4200439401A5083592777 @default.
• W4200439401 hasAuthorship W4200439401A5089163384 @default.
• W4200439401 hasAuthorship W4200439401A5089770876 @default.
• W4200439401 hasBestOaLocation W42004394011 @default.
• W4200439401 hasConcept C126322002 @default.
• W4200439401 hasConcept C143998085 @default.
• W4200439401 hasConcept C203014093 @default.
• W4200439401 hasConcept C2776364478 @default.
• W4200439401 hasConcept C2779823535 @default.
• W4200439401 hasConcept C2780007613 @default.
• W4200439401 hasConcept C2908731994 @default.
• W4200439401 hasConcept C2911091166 @default.
• W4200439401 hasConcept C71924100 @default.
• W4200439401 hasConcept C8891405 @default.
• W4200439401 hasConceptScore W4200439401C126322002 @default.
• W4200439401 hasConceptScore W4200439401C143998085 @default.
• W4200439401 hasConceptScore W4200439401C203014093 @default.
• W4200439401 hasConceptScore W4200439401C2776364478 @default.
• W4200439401 hasConceptScore W4200439401C2779823535 @default.
• W4200439401 hasConceptScore W4200439401C2780007613 @default.
• W4200439401 hasConceptScore W4200439401C2908731994 @default.
• W4200439401 hasConceptScore W4200439401C2911091166 @default.
• W4200439401 hasConceptScore W4200439401C71924100 @default.
• W4200439401 hasConceptScore W4200439401C8891405 @default.
• W4200439401 hasIssue "Supplement 1" @default.
• W4200439401 hasLocation W42004394011 @default.
• W4200439401 hasOpenAccess W4200439401 @default.
• W4200439401 hasPrimaryLocation W42004394011 @default.
• W4200439401 hasRelatedWork W2047345996 @default.
• W4200439401 hasRelatedWork W2128084036 @default.
• W4200439401 hasRelatedWork W2360955809 @default.
• W4200439401 hasRelatedWork W2404733967 @default.
• W4200439401 hasRelatedWork W2435227317 @default.
• W4200439401 hasRelatedWork W2533333370 @default.
• W4200439401 hasRelatedWork W2562053130 @default.
• W4200439401 hasRelatedWork W3032198300 @default.
• W4200439401 hasRelatedWork W3153134324 @default.

• next